Emory University news release
TB is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people with HIV. This is despite TB being a preventable and curable disease.
Although clinical trials have shown the benefit of TB preventive treatment in people with HIV, implementation in program settings was slow until a major commitment by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) in 2018. Since then, over 13 million people living with HIV worldwide have received TB preventive treatment.
A new study led by the Centers for Disease Control and Prevention’s Division of Global HIV and Tuberculosis and Emory University’s Rollins School of Public Health evaluated the real-world impact of TB preventive treatment in six countries with high TB and HIV rates (Haiti, Kenya, Nigeria, Uganda, Ukraine, and Zimbabwe). Findings were published in The Lancet HIV.
Read the full news release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #23, 13 September 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Emory University
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.